Literature DB >> 21502548

Kuhn's paradigms: are those closest to treating bladder cancer the last to appreciate the paradigm shift?

Dean F Bajorin, Harry W Herr.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21502548     DOI： 10.1200/JCO.2010.34.0471

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  10 in total

Review 1.  Muscle-invasive urothelial bladder cancer: an update on systemic therapy.

Authors:  Hayley Knollman; J Luke Godwin; Rishi Jain; Yu-Ning Wong; Elizabeth R Plimack; Daniel M Geynisman
Journal:  Ther Adv Urol       Date:  2015-12

2.  Downstaging and Survival Outcomes Associated With Neoadjuvant Chemotherapy Regimens Among Patients Treated With Cystectomy for Muscle-Invasive Bladder Cancer.

Authors:  Charles C Peyton; Dominic Tang; Richard R Reich; Mounsif Azizi; Juan Chipollini; Julio M Pow-Sang; Brandon Manley; Philippe E Spiess; Michael A Poch; Wade J Sexton; Mayer Fishman; Jingsong Zhang; Scott M Gilbert
Journal:  JAMA Oncol       Date:  2018-11-01       Impact factor: 31.777

3.  Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity.

Authors:  Elizabeth R Plimack; Jean H Hoffman-Censits; Rosalia Viterbo; Edouard J Trabulsi; Eric A Ross; Richard E Greenberg; David Y T Chen; Costas D Lallas; Yu-Ning Wong; Jianqing Lin; Alexander Kutikov; Efrat Dotan; Timothy A Brennan; Norma Palma; Essel Dulaimi; Reza Mehrazin; Stephen A Boorjian; William Kevin Kelly; Robert G Uzzo; Gary R Hudes
Journal:  J Clin Oncol       Date:  2014-05-12       Impact factor: 44.544

4.  Improving the outcome of patients with muscle invasive urothelial carcinoma of the bladder with neoadjuvant gemcitabine/cisplatin chemotherapy: A single institution experience.

Authors:  Faraj El-Gehani; Scott North; Sunita Ghosh; Peter Venner
Journal:  Can Urol Assoc J       Date:  2014-03       Impact factor: 1.862

5.  Genitourinary oncology: current status and future challenges.

Authors:  Ronald M Bukowski
Journal:  Front Oncol       Date:  2011-10-10       Impact factor: 6.244

6.  Pelvic lymph node dissection in the context of radical cystectomy: a thorough insight into the connection between patient, surgeon, pathologist and treating institution.

Authors:  Roland Seiler; George N Thalmann; Pascal Zehnder
Journal:  Res Rep Urol       Date:  2013-08-12

7.  Her2 alterations in muscle-invasive bladder cancer: Patient selection beyond protein expression for targeted therapy.

Authors:  Bernhard Kiss; Alexander W Wyatt; James Douglas; Veronika Skuginna; Fan Mo; Shawn Anderson; Diana Rotzer; Achim Fleischmann; Vera Genitsch; Tetsutaro Hayashi; Maja Neuenschwander; Christine Buerki; Elai Davicioni; Colin Collins; George N Thalmann; Peter C Black; Roland Seiler
Journal:  Sci Rep       Date:  2017-02-16       Impact factor: 4.379

Review 8.  Perioperative chemotherapy in the management of high risk upper tract urothelial cancers.

Authors:  Matthew G Kaag
Journal:  Transl Androl Urol       Date:  2020-08

9.  A Novel DNA Methylation Signature as an Independent Prognostic Factor in Muscle-Invasive Bladder Cancer.

Authors:  Zhijie Xu; Hemant Gujar; Guanghou Fu; Hamed Ahmadi; Sumeet Bhanvadia; Daniel J Weisenberger; Baiye Jin; Parkash S Gill; Inderbir Gill; Siamak Daneshmand; Kimberly D Siegmund; Gangning Liang
Journal:  Front Oncol       Date:  2021-02-15       Impact factor: 5.738

10.  Predicting response to neoadjuvant chemotherapy in bladder cancer: controversies remain with genomic DNA sequencing.

Authors:  Roland Seiler
Journal:  Transl Androl Urol       Date:  2016-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.